Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31569512 | 0.81 | SMN1; SMN2 (0.56) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL5776659 | 0.79 | MAPT (0.48) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL8538449 | 0.79 | MAPT (0.54) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL23563975 | 0.78 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL1243071 | 0.77 | SMN1; SMN2 (0.69) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL7765139 | 0.77 | MAPT (0.75) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL10031019 | 0.77 | PKM (0.51) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL17261500 | 0.76 | HSD17B10 (0.70) | MAPTSMN1; SMN2RAB9AALDH1A1TP53 | |
| SCHEMBL1243710 | 0.76 | MAPT (0.69) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL13851664 | 0.76 | MAPT (0.51) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | MAPT 4202/4885SMN1; SMN2 1921/4885NPC1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.